US logistics firm Marken has appointed two independent directors to its Board as a result of a restructuring completed last December. The appointment of Timothy Tyson and Michael O‘Donnell is the next step in Marken‘s strategy to focus on the global life sciences industry.
Tyson is a currently Chairman of Aptuit, a global pharmaceutical services company based in the US. He was CEO and President of Valeant Pharmaceuticals from 2003–2008. Prior to that, he held various leadership roles including President, Global Manufacturing & Supply at GlaxoSmithKline (GSK). During his 14 years at GSK, he led the Glaxo Dermatology and Cerenex Divisions, the US Marketing Division, and the US Sales Divisions.
O‘Donnell is currently Chairman of Verna, a company specialising in infectious control products, and non-executive Director of property developer Helical Bar. He has been an independent director on the boards of seven companies since 2008 and also acted as a consultant to one of Marken‘s clients.
Michael O Donnell
Prior to 2008, O‘Donnell was Managing Director of LGV Capital, a private equity firm, where he worked for more than a decade. He started his career at Morgan Grenfell.
Wes Wheeler, Marken‘s Chief Executive Officer, said: ‘These two independent Directors will certainly provide us with an appropriate balance of deep industry and financial experience. They also bring excellent contacts from the pharmaceutical industry and the UK financial markets, respectively, which will allow us to continue our expansion in the life sciences supply chain market.’
